MYLK3 and prostate cancer: Furthermore, prostate cancer DTCs to the bone marrow manage to escape their dormant state and initiate proliferation by downregulating TGF-β2 expression and by activating its downstream target myosin light chain (MLC) via MLC kinase (MLCK) [38].